OHSU

IRB #

IRB00009398

Title

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

Principal Investigator

Emma Scott

Study Purpose

The purpose of this study is to compare the effects, good and/or bad, of a combination of three drugs (lenalidomide, bortezomib and dexamethasone (RVD) with or without autologous stem cell transplantation, followed by lenalidomide therapy as a possible treatment for newly diagnosed multiple myeloma.

Medical Condition(s)

Multiple Myeloma

Eligibility Criteria

Participants between the ages of 18-65 that have untreated newly diagnosed Multiple Myeloma.

Age Range

18 - 65

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Dana Farber Cancer Institute

Recruitment End

02/27/2015

Compensation Provided

No


Go Back